Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis

Emma H.A. Stahlie, Evalyn E.A.P. Mulder, Sara Balduzzi, Sophie Reijers*, Charlotte L. Zuur, Willem M.C. Klop, Bernies van der Hiel, Bart A. Van de Wiel, Michel W.J.M. Wouters, Yvonne M. Schrage, Winan J. van Houdt, Dirk J. Grunhagen, Alexander C.J. van Akkooi*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Downloads (Pure)

Abstract

Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement, studies have reported varying response rates. The purpose of this systematic review and meta-analysis was to investigate the efficacy and safety of T-VEC. Of 341 publications that were identified, eight studies with a total of 642 patients were included. In patients with stage IIIB-IVM1a, the pooled complete- and overall response rate (CRR and ORR) were 41% and 64%, respectively. In patients with stage IIIB-IVM1c, the pooled CRR and ORR were 30% and 44%, respectively. In patients with stage IVM1b and IVM1c, the pooled CRR and ORR were 4% and 9%, respectively. Adverse events (AEs) were seen in 41–100% of all patients and 0–11% of AEs were severe. In conclusion, single agent T-VEC achieves the highest response rates in patients with early metastatic melanoma and is well-tolerated with generally only mild toxicities.

Original languageEnglish
Article number103705
JournalCritical Reviews in Oncology/Hematology
Volume175
DOIs
Publication statusPublished - Jul 2022

Bibliographical note

Funding Information:
None. CZ declares research funding from Bristol Myers Squibb. MW declares a research grant received from Novartis. Winan van Houdt declares advisory board/consultancy agreement and research grant received from Amgen. AvA reports advisory board and consultancy honoraria (all paid to institute and unrelated to current work) from Amgen, Bristol- Myers Squibb, Novartis; 4SC, Merck- Pfizer, MSD- Merck, Sanofi and Sirius medical. DG declares advisory board honoraria from Amgen. All remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Funding Information:
CZ declares research funding from Bristol Myers Squibb. MW declares a research grant received from Novartis. Winan van Houdt declares advisory board/consultancy agreement and research grant received from Amgen. AvA reports advisory board and consultancy honoraria (all paid to institute and unrelated to current work) from Amgen, Bristol- Myers Squibb, Novartis; 4SC, Merck- Pfizer, MSD- Merck, Sanofi and Sirius medical. DG declares advisory board honoraria from Amgen. All remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publisher Copyright:
© 2022 Elsevier B.V.

Fingerprint

Dive into the research topics of 'Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this